Acta Med. 2017, 60: 5-11

Anthelmintic Flubendazole and Its Potential Use in Anticancer Therapy

Kristýna Čáňováa, Lucie Rozkydalováb, Emil Rudolfa

aCharles University, Faculty of Medicine in Hradec Králové, Department of Medical Biology and Genetics, Hradec Králové, Czech Republic
bCharles University, Faculty of Pharmacy in Hradec Králové, Department of Pharmacology, Hradec Králové, Czech Republic

Received January 18, 2017
Accepted March 16, 2017

Flubendazole is a widely used anthelmintic drug belonging to benzimidazole group. The molecular mechanism of action of flubendazole is based on its specific binding to tubulin, which results in disruption of microtubule structure and function, and in the interference with the microtubule-mediated transport of secretory vesicles in absorptive tissues of helminths. The microtubule-disrupting properties of benzimidazole derivatives raised recently interest in these compounds as possible anti-cancer agents. In this minireview flubendazole effects towards selected human malignant cells including myeloma, leukemia, neuroblastoma, breast cancer, colorectal cancer and melanoma are discussed along with basic data on its pharmacokinetics, metabolism and toxicity.


This work was supported by the projects PRVOUK P37/01 and SVV 2016 of Charles University, Faculty of Medicine in Hradec Králové.


41 live references